To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
Within the Institute, the "Funding Research and Technology Transfer" team is at your disposal to identify the scientists and the skills you need to set up a joint project, to define the terms of a collaboration contract or study.
Whether you are an academic, a SME or an industrialist, our team informs and advices you about the possibilities of consortium assembly, technology transfer, patent licensing or use of our platforms.
The team is also at the disposal of the researchers of the institute to accompany them in achieving their valorization objectives.
Scientific result | Structural biology | Molecular mechanisms | Epigenetics | Cancer
In a study published in Science Advances, researchers from the I2BC, in collaboration with the European Institute of Chemistry and Biology (University of Bordeaux, CNRS), have developed a chimeric peptide/foldamer molecule that is resistant to proteolysis and inhibits ASF1, a potential target for anticancer treatment. The resolution of the structure of this chimera in interaction with its target, the first of its kind, reveals an unsuspected plasticity of the urea-based backbone that hugs the surface of ASF1 and maintains the same binding interface as a non-chimeric inhibitory peptide.
For about 20 years, the "Molecular Assemblies and Genome Integrity" team (CEA-Joliot/I2BC) has been studying the ASF1 protein. This 'histone chaperone', first identified as being involved in the cellular response to ionising radiation, plays a key role in the maintenance of epigenetic information during cell division. It is overexpressed in several cancer cell lines and its depletion severely compromises cell proliferation, making the protein a potential target for anti-cancer treatments. Since their initial work on the structure of the protein and its dynamic interaction with the histone dimer H3-H4, the CEA team is now trying to open up a new therapeutic avenue for certain cancers, in particular very aggressive breast cancers. Their strategy is based on the design of peptides that will associate with ASF1, instead of histones, in a sufficiently selective and specific manner to prevent ASF1 from intervening in its pathological cellular functions.
In a pilot study based on a rational strategy combining structural, computational and biochemical approaches, the team created a peptide (ip4) that inhibits the ASF1-H3-H4 dimer interaction with an affinity for ASF1 of the order of nM (Cell Chem Biol, 2019). In this study, the researchers showed in vivo that ip4 has a potential inhibitory effect on tumour growth. This work validated the relevance of ASF1 targeting and the strategy for designing ASF1 inhibitors.
The first peptides, including ip4, were too sensitive to proteolysis to be used as such in therapy, so the researchers went one step further by attempting to synthesise new peptides with a structure very close to the first ones, using synthesis bricks making them more resistant to proteolysis. Studies have shown that artificial polymers, foldamers, can reproduce well-defined structures of living molecules (proteins, nucleic acids, etc.) and in particular that they can be used to replace part of a therapeutic peptide without modifying its activity. In a new study published in Science Advances, the team joined forces with chemists from the European Institute of Chemistry and Biology (CNRS/Université Bordeaux - Guichard Research Lab) to design ASF1 inhibiting foldamers. As part of the polypeptide chain of the inhibiting peptides is regularly wound around itself (known as an alpha helix structure), the chemists chose to use oligoureas, known to mimic alpha helices. This is how the researchers designed a hybrid foldamer/peptide molecule, an ASF1 inhibitor. The resistance to proteolysis in human plasma is far superior to that of the related α-helical peptide. The insertion of 4 urea bricks in the centre of the helix is sufficient to protect the chimeric peptide from proteolysis. The crystal structure of the chimeric peptide/ASF1 complex reveals a remarkable plasticity of the urea backbone that adapts to the ASF1 surface and maintains the same binding interface as a non-chimeric inhibitory peptide. The affinity for ASF1 and the bioavailability of these new compounds still need to be optimised for effective ASF1 inhibition in cells.
Françoise Ochsenbein (email@example.com)
 Determination by liquid chromatography-mass spectrometry LEMM (SPI/DMTS, institut Joliot)
J. Mbianda, M. Bakail, C. André, G. Moal, M. E. Perrin, G. Pinna, R. Guerois, F. Becher, P. Legrand, S. Traoré, C. Douat, G. Guichard, F. Ochsenbein. Optimal Anchoring of a Foldamer Inhibitor of ASF1 Histone Chaperone 3 Through Backbone Plasticity. | Science Advances, 19 Mar 2021:Vol. 7, no. 12, eabd9153
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.